Ponicidin
Based on 4 publication(s) in Google Scholar
Ponicidin (Rubescensine B) is an orally active RIPK1 inhibitor with a Kd value of 135 nM. Ponicidin inhibits the JAK2/STAT3 pathway to induce apoptosis, activates the PI3K/Akt pathway, upregulates SIRT1 expression, alleviates oxidative stress, suppresses inflammatory responses and necroptosis, and blocks cell cycle progression. Ponicidin induces ROS production to exert antiproliferative and antiviral effects, while also improving cognitive function and reducing Aβ plaque deposition. Ponicidin can be used in studies related to hepatocellular carcinoma, Alzheimer's disease, and gastric cancer.
For research use only. We do not sell to patients.
- Purity : 99.93%
- CAS No.: 52617-37-5
- Formula: C20H26O6
- Molecular Weight:362.42
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications Citing Use of MedChemExpress (MCE) Ponicidin
More-
Cell Proliferation/Viability Assay
-
IF
-
WB
-
Cell Proliferation/Viability Assay
Biological Activity
Description
IC50 & Target
Apoptosis[1]
In Vitro
Ponicidin (5-40 μM; 24-72 h) inhibits the viability of QGY-7701 and HepG-2 human hepatocellular carcinoma cells in a dose- and time-dependent manner, with treatment at 40 μM for 72 h reducing cell viability to 9.3% (QGY-7701) and 12.7% (HepG-2), respectively[1].
Ponicidin (40 μM; 48-72 h) downregulates the mRNA and protein expression of Survivin and Bcl-2, while upregulating the mRNA and protein expression of Bax, in QGY-7701 and HepG-2 human hepatocellular carcinoma cells[1].
Ponicidin (1-50 μM; 24 h) shows no significant cytotoxicity against HT-22 mouse hippocampal neuronal cells, while Ponicidin (10 μM; 2 h pre-incubation) significantly restores the cell viability reduced by Aβ1-42 exposure[2].
Ponicidin (10 μM; pre-incubated for 2 h) significantly alleviates Aβ1-42-induced neuroinflammation in HT-22 mouse hippocampal neuron cells by downregulating pro-inflammatory cytokines (TNF-α, IL-1β) and upregulating the anti-inflammatory factor IL-10[2].
Ponicidin (10 μM; preincubated for 2 h) significantly reduces Aβ1-42-induced intracellular ROS production and oxidative stress in HT-22 mouse hippocampal neuronal cells by decreasing lipid peroxidation levels and restoring antioxidant enzyme activity[2].
Ponicidin (10 μM; 2 h pre-incubation) significantly upregulates the expression of SIRT1 in Aβ1-42-treated HT-22 mouse hippocampal neurons and modulates the activation of the PI3K/Akt pathway, while SIRT1 inhibitors reverse these effects[2].
Ponicidin (10 μM; 2 h pre-incubation) significantly enhances the expression of BDNF and NGF in Aβ1-42-treated HT-22 mouse hippocampal neuron cells via a SIRT1-mediated mechanism[2].
Ponicidin (10-50 μM; 48 h) induces dose-dependent apoptosis in human gastric cancer MKN28 cells, with the proportion of early apoptotic cells reaching 59.03% at the concentration of 50 μM[3].
Ponicidin (10-50 μM; 48 h) induces dose-dependent G0-G1 cell cycle arrest in human gastric cancer MKN28 cells, increasing the proportion of G0-G1 phase cells to 60.68% at a concentration of 50 μM. It also reduces the proportions of cells in S phase and G2-M phase[3].
Ponicidin (10-50 μM; 1-48 h) induces time- and dose-dependent activation of caspase-3 in human gastric cancer MKN28 cells, with its activity reaching 28.76% at 50 μM for 48 h[3].
Ponicidin (1.56-100 μM; 8 h) exhibits a CC50 of 59.360 μM in BV2 microglial cells, and shows low cytotoxicity at a concentration of 5 μM[4].
Ponicidin (5 μM; 8.5 h) inhibits Z-VAD (LZ) (HY-164388)-induced secretion of TNF-α (IC50 = 3.56 μM) and IL-6 (IC50 = 2.635 μM) in BV2 microglia, with significant inhibitory effects observed at a concentration of 5 μM[4].
Ponicidin (5 μM; 8.5 h) inhibits TZ-induced LDH release and protects HT22 neuronal cells from necroptosis-associated membrane damage[4].
Ponicidin (5 μM; 8.5 h) inhibits neuronal necroptosis by blocking the RIPK1-RIPK3-MLKL signaling cascade, and reduces the phosphorylation levels of RIPK1, RIPK3 and MLKL in TZ-stimulated HT22 neuronal cells[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:QGY-7701, HepG-2 human hepatocellular carcinoma cell lines
-
Concentration:5, 10, 20, 30 and 40 μM
-
Incubation Time:24, 48, 72 h
-
Result:Increased the percentage of sub-G1 apoptotic cells in both cell lines in a dose- and time-dependent manner.
Induced an apoptotic rate of 51.5% in HepG-2 cells after 40 μM treatment for 72 h.
Induced an apoptotic rate of 63.3% in QGY-7701 cells after 40 μM treatment for 72 h.
-
Cell Line:human gastric carcinoma MKN28 cells
-
Concentration:10, 25 and 50 μM
-
Incubation Time:6 h (JAK2/STAT3 phosphorylation assay); 48 h (apoptosis/signaling protein assay)
-
Result:Dose-dependently decreased phosphorylation of JAK2 and STAT3 without altering total JAK2 or STAT3 protein levels after 6 h treatment.
Dose-dependently decreased protein levels of VEGF, VEGFR2, and Bcl-2, while increasing protein levels of Bax and the active form of caspase-3 after 48 h treatment.
-
Cell Line:LZ-stimulated BV2 mouse microglial cells
-
Concentration:5 μM
-
Incubation Time:30 min (pre-incubation); 4 h (LZ stimulation)
-
Result:Effectively reduced LZ-induced phosphorylation of RIPK1, JAK1, and STAT1, and simultaneously downregulated protein levels of TNF-α and IL-6, with no significant effect on total RIPK1, JAK1, or STAT1 protein levels.
-
Cell Line:TZ-stimulated HT22 mouse hippocampal neuronal cells
-
Concentration:5 μM
-
Incubation Time:30 min (pre-incubation); 4 h (TZ stimulation)
-
Result:Effectively reduced TZ-induced phosphorylation of RIPK1, RIPK3, and MLKL, with no significant effect on total RIPK1, RIPK3, or MLKL protein levels.
-
Cell Line:HT22 mouse hippocampal neuronal cells treated with LZ-stimulated BV2 microglial cell-conditioned medium
-
Concentration:5 μM
-
Incubation Time:8 h (treated concurrently with BV2-LZ-su)
-
Result:Significantly reduced LDH release induced by BV2-LZ-su, decreasing relative LDH release from ~100% to ~70% and preserving cell membrane integrity.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:5×FAD transgenic mice (male, 12 weeks old)[4]
-
Dosage:5 mg/kg/day; 10 mg/kg/day
-
Administration:oral; daily; 30 days
-
Result:Increased novel arm entries and reduced novel arm latency (5 mg/kg, T-maze).
Increased novel arm travel distance, increased novel arm entries, and reduced novel arm latency (10 mg/kg, T-maze).
Increased novel arm travel distance and increased novel arm entries (5 mg/kg, Y-maze).
Increased novel arm travel distance, increased novel arm entries, and reduced novel arm latency (10 mg/kg, Y-maze).
Reduced target zone latency, reduced target zone errors, and reduced target zone deviation (10 mg/kg, Barnes maze).
Increased P-point duration in the probe trial (10 mg/kg, Morris water maze).
Reduced brain APP expression, reduced phosphorylation of RIPK1, RIPK3, MLKL, JAK1, and STAT1, and reduced brain TNF-α and IL-6 protein levels (5 mg/kg and 10 mg/kg, Western blot).
Reduced amyloid-beta (Aβ) plaque deposition in the cortex and hippocampus (10 mg/kg, immunohistochemistry).
Chemical Information
-
CAS No. 52617-37-5
-
Appearance Solid
-
Molecular Weight 362.42
-
Formula C20H26O6
-
Color White to off-white
-
SMILES
O[C@]12[C@]3(C4=O)[C@]5([H])C6([C@](O[C@@]3([H])[C@](CC5)([H])C4=C)([H])O2)[C@](C(C)(CC[C@@H]6O)C)([H])[C@@H]1O
-
Synonyms
Rubescensine B
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Phytomedicine
Ponicidin promotes ferroptosis to enhance treatment sensitivity in Lenvatinib-resistant hepatocellular carcinoma cells through regulation of KEAP1/NRF2. [Abstract]2025 Jul 25:143:156824. PMID: 40382941 -
Phytomedicine
Ponicidin inhibited gallbladder cancer proliferation and metastasis by decreasing MAGEB2 expression through FOXO4. [Abstract]2023 Jun:114:154785. PMID: 37002972
Ponicidin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2023 Jun:114:154785. [Abstract]
Ponicidin (5, 20 µM; 48 h) suppresses proliferation of NOZ and GBC-SD cells effectively.
Ponicidin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2023 Jun:114:154785. [Abstract]
Ponicidin (5, 20 µM; 24 h) decreases the migration and invasion capabilities of NOZ and GBC-SD cells.
Ponicidin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2023 Jun:114:154785. [Abstract]
Ponicidin (5, 20 µM) significantly reduces the expression of mesenchymal phenotypes biomarkers, vimentin and N-cadherin, while upregulating the expression of E-cadherin (a distinguishing factor of epithelial cells), in NOZ and GBC-SD cells.
Ponicidin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2023 Jun:114:154785. [Abstract]
Ponicidin (10, 20 mg/kg; p.o.; every 2 days for 4 weeks) significantly inhibits subcutaneous tumor growth in mice in a dose-dependent manner.
-
Mol Biol Rep
Ponicidin attenuates Aβ1-42-induced hippocampal cell injury through SIRT1 and PI3K/Akt pathways. [Abstract]2025 Jul 24;52(1):752. PMID: 40705095 -
Biol Pharm Bull
Ponicidin Induces Apoptosis of Murine Melanoma by Inhibiting the NF-κB Signaling Pathway. [Abstract]2023;46(6):803-810. PMID: 37258145
Solvent & Solubility
In Vitro:
DMSO : 125 mg/mL (344.90 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (5.74 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (5.74 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Protocol for Water Maze
The Morris Water Maze is a rodent spatial learning and memory assay in which a mouse or rat swims in opaque water to find an escape platform; in the hidden-platform version, the animal cannot see the platform and must use distal extra-maze cues to learn its fixed spatial location. The assay primarily measures hippocampus-dependent spatial learning during acquisition trials and spatial reference memory during probe trials after platform removal; readouts include escape latency, swim path length, swim speed, quadrant occupancy, platform-site crossings, and proximity to the former platform location.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
Alzheimer’s Disease Modeling
Alzheimer’s Disease (AD) is a neurodegenerative disorder characterized by a progressive decline in cognitive functions and loss of specific types of neurons and synapses. Alzheimer's symptoms can be simulated in mice by injecting drugs (such as Aβ) or genetically modified.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
Purity & Documentation
-
Data Sheet (300 KB)
-
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
-
Handling Instructions (2659 KB)
References
[1]. Zhang JF, et al. Ponicidin inhibits cell growth on hepatocellular carcinoma cells by induction of apoptosis. Dig Liver Dis. 2007 Feb;39(2):160-6. [Content Brief]
[2]. Wang C, et al. Ponicidin attenuates Aβ1-42-induced hippocampal cell injury through SIRT1 and PI3K/Akt pathways. Mol Biol Rep. 2025;52(1):752. Published 2025 Jul 24. [Content Brief]
[3]. Liu YF, et al. Ponicidin induces apoptosis via JAK2 and STAT3 signaling pathways in gastric carcinoma. Int J Mol Sci. 2015;16(1):1576-1589. Published 2015 Jan 12. [Content Brief]
[4]. Hu H, et al. Ponicidin ameliorates Alzheimer's disease through dual inhibition of RIPK1-mediated neuroinflammation and necroptosis. Int Immunopharmacol. 2026;171:116095. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.7592 mL | 13.7961 mL | 27.5923 mL | 68.9807 mL |
| 5 mM | 0.5518 mL | 2.7592 mL | 5.5185 mL | 13.7961 mL | |
| 10 mM | 0.2759 mL | 1.3796 mL | 2.7592 mL | 6.8981 mL | |
| 15 mM | 0.1839 mL | 0.9197 mL | 1.8395 mL | 4.5987 mL | |
| 20 mM | 0.1380 mL | 0.6898 mL | 1.3796 mL | 3.4490 mL | |
| 25 mM | 0.1104 mL | 0.5518 mL | 1.1037 mL | 2.7592 mL | |
| 30 mM | 0.0920 mL | 0.4599 mL | 0.9197 mL | 2.2994 mL | |
| 40 mM | 0.0690 mL | 0.3449 mL | 0.6898 mL | 1.7245 mL | |
| 50 mM | 0.0552 mL | 0.2759 mL | 0.5518 mL | 1.3796 mL | |
| 60 mM | 0.0460 mL | 0.2299 mL | 0.4599 mL | 1.1497 mL | |
| 80 mM | 0.0345 mL | 0.1725 mL | 0.3449 mL | 0.8623 mL | |
| 100 mM | 0.0276 mL | 0.1380 mL | 0.2759 mL | 0.6898 mL |
Keywords
- Ponicidin
- 52617-37-5
- Rubescensine B
- RIP kinase
- Apoptosis
- Reactive Oxygen Species (ROS)
- JAK
- STAT
- PI3K
- Akt
- Sirtuin
- Necroptosis
- Amyloid-β
- PI3K/Akt pathway
- mouse RIPK1
- JAK2/STAT3 pathway
- Alzheimer's disease
- SIRT1
- HepG-2
- HT-22 mouse hippocampal neuronal cells
- QGY-7701
- gastric carcinoma
- hepatocellular carcinoma
- Inhibitor
- inhibitor
- inhibit